There were 780 press releases posted in the last 24 hours and 200,672 in the last 365 days.

CytoDyn Announces Investment Community Conference Call for August 19, 2016

VANCOUVER, Washington, Aug. 17, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Friday, August 19, 2016, at 1:30 p.m. PT / 4:30 p.m. ET to provide an update on clinical trial and regulatory developments.

Conference Call and Webcast Instructions
CytoDyn’s management team will host a conference call and live audio webcast on August 19, 2016 at 1:30 p.m. PT / 4:30 p.m. ET.

Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).

A live audio webcast may also be accessed via CytoDyn’s corporate web site at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days.  Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.  The webcast can also be accessed via the following link: http://cytodyn.equisolvewebcast.com/inv-call-8-19-16.

A replay of the conference call will be available until October 19, 2016.  To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13643977.

CONTACTS:
Investors:
LHA
Jody Cain
Office: 310-691-7100
E-mail: jcain@lhai.com

Media:
RooneyPartners
Marion Janic
Office: 212-223-4017
Email: mjanic@rooneyco.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.